-
Weekly Pharma News Review | PharmaSources.com (1114-1118)
Industry Data
PharmaSources.comNovember 21, 2022
The news review of this week is from November 14 to 18, covering a total of 23 pieces of information in 3 sections, i.e., drug review, R&D, and business.
-
Weekly Pharma News Review | PharmaSources.com (1107-1111)
Industry Data
PharmaSources.comNovember 14, 2022
The news review of this week is from November 7 to 11, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
-
Weekly Pharma News Review | PharmaSources.com (1031-1104)
Industry Data
PharmaSources.comNovember 08, 2022
The news review of this week is from October 31 to November 4, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
-
Weekly Pharma News Review | PharmaSources.com (1024-1028)
Industry Data
PharmaSources.comOctober 31, 2022
The news review of this week is from October 24 to 28, covering a total of 23 pieces of information in 4 sections, i.e., drug review, R&D, business and listing.
-
Weekly Pharma News Review | PharmaSources.com (1017-1021)
Industry Data
PharmaSources.comOctober 24, 2022
The news review of this week is from October 17 to 21, covering a total of 21 pieces of information in 3 sections, i.e., drug review, R&D, and listing.
-
Weekly Pharma News Review | PharmaSources.com (1008-1014)
Industry Data
PharmaSources.comOctober 18, 2022
The most exciting thing for the industry is the first-in-class drug, Dorzagliatin Tablets, which is independently researched and developed by Hua Medicine was approved for marketing, becoming the first approved new drug for GKA diabetes in the world.
-
Weekly Pharma News Review | PharmaSources.com (0926-0930)
Industry Data
PharmaSources.comOctober 08, 2022
The news reviewed this week is from September 26 to 30, covering a total of 26 pieces of information in 4 sections, i.e. drug review, R&D, business and policy.
-
Weekly Pharma News Review | PharmaSources.com (0919-0923)
Industry Data
PharmaSources.comSeptember 26, 2022
The news reviewed this week is from September 19 to 23, covering a total of 25 pieces of information in 4 sections, i.e. drug review, R&D, and business and listing.
-
Weekly Pharma News Review | PharmaSources.com (0912-0916)
Industry Data
PharmaSources.comSeptember 20, 2022
The news reviewed this week is from September 12 to 16, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
-
Weekly Pharma News Review | PharmaSources.com (0905-0909)
Industry Data
PharmaSources.comSeptember 14, 2022
The news review of this week is from September 5 to 9, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
The news review of this week is from November 14 to 18, covering a total of 23 pieces of information in 3 sections, i.e., drug review, R&D, and business.
The news review of this week is from November 7 to 11, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
The news review of this week is from October 31 to November 4, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
The news review of this week is from October 24 to 28, covering a total of 23 pieces of information in 4 sections, i.e., drug review, R&D, business and listing.
The news review of this week is from October 17 to 21, covering a total of 21 pieces of information in 3 sections, i.e., drug review, R&D, and listing.
The most exciting thing for the industry is the first-in-class drug, Dorzagliatin Tablets, which is independently researched and developed by Hua Medicine was approved for marketing, becoming the first approved new drug for GKA diabetes in the world.
The news reviewed this week is from September 26 to 30, covering a total of 26 pieces of information in 4 sections, i.e. drug review, R&D, business and policy.
The news reviewed this week is from September 19 to 23, covering a total of 25 pieces of information in 4 sections, i.e. drug review, R&D, and business and listing.
The news reviewed this week is from September 12 to 16, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
The news review of this week is from September 5 to 9, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Pharma Sources Insight JUNE2022
